



Aenova Cannabinoids in Softgels

Cannabinoids in softgels

Cannabinoids - Over 100 cannabinoids can interact with the human endocannabinoid system

Market potential - Cannabinoid products evolving into a \$6 bn market

Ideal pharmaceutical product - Softgels representing the ideal pharmaceutical form for cannabinoids

Aenova Kirchberg site

40 years of experience - Deep expertise in development, production and regulations of pharmaceutical softgels

A leading specialist in Softgels

Legal status of product & freedom to operate - In Switzerland medicinal cannabis has no THC limit, allowing undisputed handling of the product

Advantages of CBD softgels



Protection of Cannabinoid API
CBD sensitive to light and oxidation



Better BA
Increased GI solubility, intestinal permeability and enhanced lymphatic absorption



Increased patient compliance
Ease of transport and dosage



Dosage range easily adjustable
Change of concentration or capsule size



Wide range of shapes and sizes



Marketing advantages
Elegant appearance and efficient smell and taste masking

One stop shop



Supply of high-quality medicinal cannabis
Possibility to access Swiss high quality raw material



Worldwide footprint
Export to almost 100 countries



Development of suitable formulation
GMP capabilities including analytics and ICH stability



Supply of clinical testing material



Complete product chain including packaging and commercial supply
From first trials to commercial production



Regulatory support
DRA support for WW registrations

Impeccable softgel services of Aenova *



Quality
0.8% justified complaint rate
0.3% leaker complaint rate



Cost
0 batch loss on quality
98.9% yield



Delivery
97% OTD
(on time delivery)

Certificates

Swissmedic, US FDA, Chinese FDA, Turkish MOH, Russian MOH, Saudi Arabian SFDA, BRC, AVSV
ISO 14001:2015